keyword
MENU ▼
Read by QxMD icon Read
search

Quo vadis

keyword
https://www.readbyqxmd.com/read/29873934/catalytic-transformations-of-functional-cyclic-organic-carbonates-quo-vadis
#1
Wusheng Guo, Jose Enrique Gomez, Alex Cristofol, Jianing Xie, Arjan Willem Kleij
Functionalized cyclic organic carbonates and related heterocycles have emerged as highly versatile heterocyclic substrates for ring-opening and decarboxylative catalytic transformations allowing for the development of new stereo- and enantioselective C-N, C-O, C-C, C-S and C-B bond formation reactions. Transition metal mediated conversions have only recently been rejuvenated as powerful approaches towards the preparation of more complex molecules. This minireview will highlight the potential of cyclic carbonates and structurally related heterocycles with a focus on their synthetic value and the mechanistic manifolds that are involved upon their conversión...
June 6, 2018: Angewandte Chemie
https://www.readbyqxmd.com/read/29869705/-cause-of-death-statistics-and-icd-quo-vadis
#2
REVIEW
Olaf Eckert, Ulrich Vogel
The International Statistical Classification of Diseases and Related Health Problems (ICD) is the worldwide binding standard for generating underlying cause-of-death statistics. OBJECTIVES: What are the effects of former revisions of the ICD on underlying cause-of-death statistics and which opportunities and challenges are becoming apparent in a possible transition process from ICD-10 to ICD-11?This article presents the calculation of the exploitation grade of ICD-9 and ICD-10 in the German cause-of-death statistics and quality of documentation...
June 5, 2018: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
https://www.readbyqxmd.com/read/29796557/quo-vadis-unimolecular-electronics
#3
REVIEW
Robert Melville Metzger
This paper reviews the present status of unimolecular electronics (UME). The field started in the 1970s with a hope that some day organic molecules (∼2 nm in size), when used as electronic components, would challenge Si-based inorganic electronics in ultimate-high-density integrated circuits. The technological push to ever smaller inorganic device sizes (Moore's "law") was driven by a profit motive and by vast investments. UME, the underfunded pauper, may have lost that "race to the bottom", but some excellent science is left to be done...
May 25, 2018: Nanoscale
https://www.readbyqxmd.com/read/29794810/supportive-care-in-cancer-quo-vadis
#4
Jean Klastersky
No abstract text is available yet for this article.
May 22, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29777333/quo-vadis-lactoferrin
#5
EDITORIAL
Hans J Vogel, Antimo Cutone, Maria S Lepanto, Luigi Rosa, Piera Valenti
No abstract text is available yet for this article.
June 2018: Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine
https://www.readbyqxmd.com/read/29739614/automated-classification-of-celiac-disease-during-upper-endoscopy-status-quo-and-quo-vadis
#6
M Gadermayr, G Wimmer, H Kogler, A Vécsei, D Merhof, A Uhl
A large amount of digital image material is routinely captured during esophagogastroduodenoscopies but, for the most part, is not used for confirming the diagnosis process of celiac disease which is primarily based on histological examination of biopsies. Recently, considerable effort has been undertaken to make use of image material by developing semi- or fully-automated systems to improve the diagnostic workup. Recently, focus was especially laid on developing state-of-the-art deep learning architectures, exploiting the endoscopist's expert knowledge and on making systems fully automated and thereby completely observer independent...
April 27, 2018: Computers in Biology and Medicine
https://www.readbyqxmd.com/read/29736589/quo-vadis-vaginal-mesh-in-pelvic-organ-prolapse
#7
EDITORIAL
Stephen Jeffery, Jan-Paul Roovers
No abstract text is available yet for this article.
May 7, 2018: International Urogynecology Journal
https://www.readbyqxmd.com/read/29727331/10th-anniversary-of-alpps-lessons-learned-and-quo-vadis
#8
Hauke Lang, Eduardo de Santibañes, Hans J Schlitt, Massimo Malagó, Thomas van Gulik, Marcel A Machado, Elio Jovine, Stefan Heinrich, Giuseppe Maria Ettorre, Albert Chan, Roberto Hernandez-Alejandro, Ricardo Robles Campos, Per Sandström, Michael Linecker, Pierre-Alain Clavien
OBJECTIVE: Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) has been tested in various indications and clinical scenarios, leading to steady improvements in safety. This report presents the current status of ALPPS. SUMMARY BACKGROUND DATA: ALPPS offers improved resectability, but drawbacks are regularly pointed out regarding safety and oncologic benefits. METHODS: During the 12th biennial congress of the European African-Hepato-Pancreato-Biliary Association (Mainz, Germany, May 23-26, 2017) an expert meeting "10th anniversary of ALPP" was held to discuss indications, management, mechanisms of regeneration, as well as pitfalls of this novel technique...
May 1, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29708117/treatment-of-malignant-pleural-mesothelioma-lessons-learned-and-quo-vadis
#9
EDITORIAL
Servet Bölükbas, Michael Eberlein
No abstract text is available yet for this article.
March 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29666934/quo-vadis-do-immunotherapies-have-a-role-in-glioblastoma
#10
REVIEW
Sylvia C Kurz, Patrick Y Wen
PURPOSE OF REVIEW: More effective therapies for glioblastoma are urgently needed. Immunotherapeutic strategies appear particularly promising and are therefore intensively studied. This article reviews the current understanding of the immunosuppressive glioblastoma microenvironment, discusses the rationale behind various immunotherapies, and outlines the findings of several recently published clinical studies. RECENT FINDINGS: The results of CheckMate-143 indicated that nivolumab is not superior to bevacizumab in patients with recurrent glioblastoma...
April 18, 2018: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/29625709/digital-pathology-quo-vadis
#11
EDITORIAL
Eric F Glassy
No abstract text is available yet for this article.
April 3, 2018: Pathology
https://www.readbyqxmd.com/read/29610775/editorial-digital-complete-dentures-quo-vadis
#12
Bernd Kordaß
No abstract text is available yet for this article.
2018: International Journal of Computerized Dentistry
https://www.readbyqxmd.com/read/29610128/renin-angiotensin-aldosterone-system-inhibitors-for-right-ventricular-dysfunction-in-tetralogy-of-fallot-quo-vadis
#13
EDITORIAL
Sushma Reddy, Daniel Bernstein, Jane W Newburger
No abstract text is available yet for this article.
April 3, 2018: Circulation
https://www.readbyqxmd.com/read/29606064/ketamine-quo-vadis
#14
Charles B Nemeroff
No abstract text is available yet for this article.
April 1, 2018: American Journal of Psychiatry
https://www.readbyqxmd.com/read/29589875/evidence-based-medicine-2018-quo-vadis
#15
EDITORIAL
Andrew Miles
No abstract text is available yet for this article.
February 2018: Journal of Evaluation in Clinical Practice
https://www.readbyqxmd.com/read/29553749/drug-delivery-in-cancer-therapy-quo-vadis
#16
Zheng-Rong Lu, Peter Qiao
The treatment of malignancies has undergone dramatic changes in the past few decades. Advances in drug delivery techniques and nanotechnology have allowed for new formulations of old drugs, so as to improve the pharmacokinetics, to enhance accumulation in solid tumors, and to reduce the significant toxic effects of these important therapeutic agents. Here, we review the published clinical data in cancer therapy of several major drug delivery systems, including targeted radionuclide therapy, antibody-drug conjugates, liposomes, polymer-drug conjugates, polymer implants, micelles, and nanoparticles...
March 22, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29547420/smarttots-quo-vadis
#17
Laszlo Vutskits
No abstract text is available yet for this article.
April 2018: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/29490803/quo-vadis-point-of-care-diagnostics-report-ii-of-the-swiss-symposium-in-point-of-care-diagnostics-2017
#18
Marc E Pfeifer
U.S. studies show that the global point-of-care (POC) diagnostics market will reach $40.5 bn by 2022, with a compound annual growth rate (CAGR) of 10%. This is one of the reasons why HES-SO Valais-Wallis and CSEM, acting on behalf of the NTN Swiss Biotech thematic platform in vitro Diagnostics (TP IVD), invited interested parties on October 26, 2017 to the SWISS SYMPOSIUM in Point-of-Care Diagnostics (see CHIMIA No. 12/2017). We now bring the second report on the future prospects of POC diagnostics.
February 1, 2018: Chimia
https://www.readbyqxmd.com/read/29462830/-quo-vadis-data-linkage-in-germany-an-initial-inventory
#19
Stefanie March, Manfred Antoni, Joachim Kieschke, Bianca Kollhorst, Birga Maier, Gabriele Müller, Murat Sariyar, Mandy Schulz, Swart Enno, Jan Zeidler, Falk Hoffmann
In recent years, linking different data sources, also called data linkage or record linkage, to address scientific questions, is being increasingly used in Germany. However, there are very few published reports and new projects develop the necessary tools independently of each other. Therefore, a team of researchers joined together to exchange their experiences on data linkage and to give suggestions on how linkage could be done for scientists, reviewers as well as members of data privacy boards and ethics committees...
March 2018: Das Gesundheitswesen
https://www.readbyqxmd.com/read/29367715/biomarkers-in-chronic-graft-versus-host-disease-quo-vadis
#20
D Wolff, H Greinix, S J Lee, T Gooley, S Paczesny, S Pavletic, F Hakim, F Malard, M Jagasia, A Lawitschka, J A Hansen, D Pulanic, E Holler, A Dickinson, E Weissinger, M Edinger, S Sarantopoulos, K R Schultz
Biomarkers are increasingly used for diagnosis and treatment of transplant-related complications including the first biomarker-driven interventional trials of acute graft-versus-host disease (GvHD). In contrast, the development of biomarkers of chronic GvHD (cGvHD) has lagged behind due to a broader variety of manifestations, overlap with acute GvHD, a greater variation in time to onset and maximum severity, and lack of sufficient patient numbers within prospective trials. An international workshop organized by a North-American and European consortium was held in Marseille in March 2017 with the goal to discuss strategies for future biomarker development to guide cGvHD therapy...
January 24, 2018: Bone Marrow Transplantation
keyword
keyword
68327
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"